Recent progress in sodium channel modulators for pain |
| |
| Affiliation: | 1. Worldwide Medicinal Chemistry, Pfizer Neusentis, The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, UK;2. Electrophysiology, Pfizer Neusentis, 4222 Emperor Blvd., Durham, NC, USA;3. Chemistry, Pfizer Neusentis, 4222 Emperor Blvd., Durham, NC, USA;4. Electrophysiology, Pfizer Neusentis, The Portway Building, Granta Park, Great Abington, Cambridge CB21 6GS, UK |
| |
| Abstract: | Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda®, Synchropatch® and Qube®. Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery. |
| |
| Keywords: | Voltage-gated sodium channels Electrophysiology screening Sodium channel toxins Sodium channel structure Sodium channel drugs |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
